{
    "code": "52027022",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027022",
    "time": "2018-04-27 03:07:17",
    "許可證字號": "衛部藥輸字第027022號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/02\/21",
    "發證日期": "106\/02\/21",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202702204",
    "中文品名": "瑞骨卓150毫克膜衣錠",
    "英文品名": "Reosteo 150mg Tablets",
    "適應症": "治療及預防停經後婦女之骨質疏鬆症。",
    "劑型": "116膜衣錠",
    "包裝": "1-1000錠鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "RISEDRONATESODIUM"
    ],
    "限制項目": "02輸　入 1EPhase IV Study 24監視期滿學名藥",
    "申請商名稱": "620111B655  旭能醫藥生技股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F070067000  PHARMASCIENCE INC.",
        "製造廠廠址": "6111 ROYALMOUNT AVENUE 100, MONTREAL, QUEBEC, CANADA, H4P 2T4",
        "製造廠公司地址": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200096300",
            "成分名稱": "RISEDRONATE SODIUM",
            "含量描述": "Risedronate Sodium Hemipentahydrate",
            "含量": "150.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Reosteo 150mg Tablets - PMS insert 20170307-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027022&Seq=001&Type=9"
        },
        {
            "title": "Reosteo 150mg Tablets box revised-106-03-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027022&Seq=001&Type=8"
        }
    ]
}